SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high conviction as Dr. PSS's recent presentation on Anktiva's potential to prevent and cure cancer sparks widespread community excitement, fueling intense short squeeze speculation and institutional interest amidst perceived regulatory resistance.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to its strategic pivot from Bitcoin mining to a high-performance computing and AI data center provider, backed by significant power infrastructure acquisitions and bullish institutional coverage. The community is actively discussing its high short interest and long-term growth potential as an AI infrastructure play, amidst varying views on short-term price action.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending with notable pre-earnings strength, fueled by expectations of an 18th consecutive beat and raise and the continued integration of its OpenAI partnership into its AI marketing platform. Community sentiment is divided between strong bullish conviction in its proprietary data moat and concerns over broader software sector headwinds potentially leading to a "sell the news" event.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following a significant strategic collaboration with Astellas for its VIR-5500 prostate cancer asset, bolstered by positive Phase 1 trial data and multiple analyst upgrades. The community is actively discussing the substantial financial commitment and the potential for a short squeeze, given the tight float and notable short interest.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as a key director's substantial insider purchase and a new LPGA marketing partnership signal strong long-term confidence, even while the community debates its undervalued status, the impact of increased growth-oriented expenses, and ongoing buyout speculation.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday (WDAY) is trending after its latest earnings release, which, despite beating estimates, triggered a significant aftermarket sell-off amidst concerns about future subscription growth and mixed reactions to its AI acquisition strategy and recent leadership changes. The community is sharply divided, with bulls viewing the dip as a buying opportunity while bears contend that AI disruption fundamentally challenges the SaaS business model, anticipating further declines for the enterprise software giant.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited (ANPA) is trending due to its acquisition of TikTok icon Khaby Lame's core company, sparking community excitement about potential explosive growth in digital content. However, the move is also drawing significant skepticism and warnings of a pump-and-dump, with many questioning its valuation compared to fundamentals.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending following a significant $500 million equipment loan from a leading financial institution, perceived by the community as strong institutional backing for its massive 11GW AI energy campus, Project Matador. This pivotal financing has sparked active discussions about an imminent tenant announcement and positions FRMI as a high-volatility, event-driven play in the critical AI infrastructure sector.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as the community eagerly anticipates its Q3 earnings, with discussions focused on updated guidance and the potential impact of a recent FDA safety notice regarding specific product lots. Persistent speculation surrounds a possible short squeeze or outright acquisition, fueled by the stock's perceived undervaluation and strategic repositioning, despite ongoing frustrations with its price action.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is actively discussed ahead of its earnings release, with community sentiment divided between concerns over Tesla's emerging solar presence and strong conviction in FSLR's US manufacturing and thin-film technology to capitalize on increasing utility-scale demand from AI data centers and favorable trade policies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6% - Time to Sell?

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 7.6% - Time to Sell...

Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP boosted its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 25.9% in the 3rd quarter, according to its most recent filing with the Securities and...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat...

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know 

Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3% - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 9.3% - Here's What Happened...

Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains

Corvus Pharmaceuticals (NASDAQ:CRVS) presented new Phase I results for oral soquelitinib in moderate-to-severe atopic dermatitis (AD), highlighting updated efficacy, durability, and safety findings...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's Why...

<ul class="summary-bullets"><li>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.</li><li>This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.</li><li>The company expects to close the offering on or about Jan. 23, 2026.</li></ul>Corvus Pharmaceuticals Inc. (CRVS) shares were up&nbsp;more than 7% in&nbsp;Thursday’s&nbsp;pre-market trade after the company announced an upsized public stock offering.Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15. The company stated that underwriters have a 30-day option to purchase an additional 1.18 million shares.The company expects to close the offering on or about Jan. 23, 2026.<h2 class="st-heading-2">Use Of Net Proceeds</h2>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma clinical trials, sales and marketing and administrative expenses.<h2 class="st-heading-2">Positive Atopic Dermatitis Trial Results</h2>Corvus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-crvs-stock-rising-today/cmUuNzGR4aM">announced</a> on Tuesday that cohort 4 of its placebo-controlled trial showed favorable safety and efficacy results, consistent with those of the previous three cohorts.Corvus stated that all patients in cohort 4 had completed the 56-day treatment course and had similar baseline characteristics to those in the previous cohort. However, they had a higher mean baseline EASI (Eczema Area and Severity Index) score compared to patients in cohorts 1 and 2.“The results from cohort 4 increase our confidence that soquelitinib could become a leading oral therapy for the treatment of atopic dermatitis,” said Corvus CEO Richard A. Miller.<h2 class="st-heading-2">Retail Sounds Optimistic</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CRVS">Corvus Pharmaceuticals</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘extremely high’ levels.One bullish user on the platform pointed to inbound partnerships and institutional buying, stating that the stock could “double again soon.”<stembedurl>https://stocktwits.com/fubar444/message/642514507</stembedurl>Another user stated that the CRVS stock will “rocket” once the offering closes.<stembedurl>https://stocktwits.com/SleepyDon/message/642502522</stembedurl><a href="https://stocktwits.com/symbol/CRVS">CRVS stock</a> is up 188% year-to-date and 324% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-indian-antitrust-regulator-prevent-global-financial-records-38-billion-fine/cmUzwavR4QZ">Apple Seeks To Prevent India’s Antitrust Regulator From Accessing Global Financial Records As It Fears A $38 Billion Fine: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corvus Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

Equity

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc